Concepedia

Stephan Kopytek

SK

Statistics

Publications

6

Citations

269

H-Index

6

Active since

2000

Affiliations

Bristol-Myers Squibb (United States)(Current)

Texas A&M University

Stephan Kopytek is an author at Bristol-Myers Squibb (United States) specializing in oncology, life sciences, and medicine.

Publications per year

2000–2022

6

Publications

6

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Amer M. Zeidan, Daniel J. DeAngelo, Jeanne Palmer et al. · Annals of Hematology · 2022 · 94 citations · Full text

, , +17

Chemically induced dimerization of dihydrofolate reductase by a homobifunctional dimer of methotrexate

Stephan Kopytek, Robert F. Standaert, John C. D. Dyer et al. · Chemistry & Biology · 2000 · 53 citations · Full text

, , +10

Resistance to Methotrexate Due to AcrAB-Dependent Export from <i>Escherichia coli</i>

Stephan Kopytek, John C. D. Dyer, Gwendowlyn S. Knapp et al. · Antimicrobial Agents and Chemotherapy · 2000 · 45 citations · Full text

, , +17

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials

Fiona Sewell, Kathryn Chapman, Paul Baldrick et al. · Regulatory Toxicology and Pharmacology · 2014 · 34 citations · Full text

, , +15

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

Rama Krishna Narla, Hardik Modi, Daniel E. Bauer et al. · Cancer Immunology Immunotherapy · 2021 · 33 citations · Full text

, , +14

1–5 of 6